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Some clinicians assess the efficacy of pralidoxime in organo-
phosphorus (OP) poisoned patients by measuring reactivation of 
butyrylcholinesterase (BuChE). However, the degree of BuChE 
inhibition varies by OP insecticide, and it is unclear how well oxi-
mes reactivate BuChE in vivo. We aimed to assess the usefulness 
of BuChE activity to monitor pralidoxime treatment by studying 
its reactivation after pralidoxime administration to patients with 
laboratory-proven World Health Organization (WHO) class II OP 
insecticide poisoning. Patient data were derived from 2 studies, 
a cohort study (using a bolus treatment of 1 g pralidoxime chlo-
ride) and a randomized controlled trial (RCT) (comparing 2 g 
pralidoxime over 20 min, followed by an infusion of 0.5 g/h, with 
placebo). Two grams of pralidoxime variably reactivated BuChE 
in patients poisoned by 2 diethyl OP insecticides, chlorpyrifos and 
quinalphos; however, unlike acetylcholinesterase reactivation, this 
reactivation was not sustained. It did not reactivate BuChE inhib-
ited by the dimethyl OPs dimethoate or fenthion. The 1-g dose 
produced no reactivation. Pralidoxime produced variable reacti-
vation of BuChE in WHO class II OP-poisoned patients according 
to the pralidoxime dose administered, OP ingested, and individual 
patient. The use of BuChE assays for monitoring the effect of pra-
lidoxime treatment is unlikely to be clinically useful.
Key Words: organophosphorus insecticides; butyrylcholinest-
erase; pralidoxime; marker; human poisoning.
InTROduCTIOn
Organophosphorus (OP) insecticide self-poisoning is 
a major global health problem (Bertolote et  al., 2006; 
Jeyaratnam, 1990), with hundreds of thousands of deaths each 
year in rural regions of the developing world (Eddleston, 2000; 
Gunnell et al., 2007). Although the more toxic World Health 
Organization (WHO) class  I  OPs (those with rat oral LD
50
s 
of less than 50 mg/kg; World Health Organization, 2010) are 
being removed from agricultural practice, WHO class  II OPs 
(with rat oral LD
50
 of 50 mg/kg or more) are still widely used.
OP insecticides inhibit the enzymes acetylcholinesterase 
(AChE, EC 3.1.1.7) and butyrylcholinesterase (BuChE, EC 
3.1.1.8), although some require metabolism to an oxon form 
via cytochrome P450 enzymes before becoming active (Lotti, 
2001). Clinical features arise from inhibition of AChE caus-
ing overstimulation at cholinergic synapses in the autonomic 
nervous system, neuromuscular junction, and central nervous 
system (Ballantyne and Marrs, 1992). BuChE inhibition, in 
contrast, appears not to result in clinical features (Ballantyne 
and Marrs, 1992; Lotti, 2001). Management (Eddleston et al., 
2008a; Johnson et  al., 2000) involves resuscitation and the 
administration of the muscarinic antagonist atropine (Heath 
and Meredith, 1992) and an oxime AChE reactivator such as 
pralidoxime (Eyer, 2003). The beneficial effects of atropine are 
clear (Freeman and Epstein, 1955; Heath and Meredith, 1992; 
Johnson et  al., 2000). By contrast, the effect of pralidoxime 
remains unclear (Buckley et al., 2011).
Clinicians have used reactivation of cholinesterase activity in 
blood as a way of measuring the effect of pralidoxime treatment 
in poisoned patients. Red-cell AChE assays should be more 
reliable because clinical effects result from synaptic AChE 
inhibition, and red-cell AChE has a close kinetic similarity with 
synaptic AChE. However, assays for BuChE activity are widely 
available and routinely performed and can be done on routinely 
sampled plasma samples, whereas AChE assays require whole 
blood samples that are rapidly cooled (Eyer, 2003). Therefore, 
BuChE assays have been used by some physicians to grade 
severity and to assess reactivation and pralidoxime efficacy 
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RESPONSE OF BuChE TO PRALIDOXIME
(Abdullat et al., 2006; Khan et al., 2001; Kwong, 2002; Lee 
and Tai, 2001; Namba et al., 1971; Pham, 2007).
Using BuChE for this purpose is complicated by the vari-
ability in BuChE inhibition and perhaps BuChE reactivation 
by pralidoxime, according to the OP (Eddleston et  al., 2005, 
2008b). In vitro studies have reported mixed results as to 
whether pralidoxime can reactivate BuChE inhibited by WHO 
class I OPs (Aurbek et al., 2009; Jafari and Pourheidari, 2006; 
Musilova et al., 2009). In addition, BuChE becomes aged after 
inhibition by both diethyl and dimethyl OPs so that it becomes 
unresponsive to reactivation by pralidoxime (Aurbek et  al., 
2009).
It is, therefore, currently unclear whether measurement of 
BuChE activity might be appropriate for monitoring pralidoxime 
treatment in class II OP-poisoned patients. The aim of this study 
was to examine the reactivation of BuChE in vivo after pral-
idoxime treatment in Sri Lankan patients with laboratory-proven 
WHO class  II OP insecticide poisoning. The data used were 
derived from 2 published studies: an observational cohort study 
(Eddleston et al., 2005) and a randomized controlled trial (RCT) 
(Eddleston et  al., 2009a) using 2 different regimens of pral-
idoxime chloride. Analysis of these 2 studies has not previously 
assessed the effect of pralidoxime on reactivation of BuChE.
MaTERIalS and METHOdS
Institutional Review Board approval was received from the Faculty of 
Medicine Ethics Committee, Colombo, and Oxfordshire Clinical Research 
Ethics Committee. The RCT was established in response to systematic reviews 
(Buckley et al., 2005; Eddleston et al., 2002) that showed a lack of evidence 
for pralidoxime effectiveness and has been published in full (Eddleston et al., 
2009a). The results by RCT indicated that pralidoxime was not effective; as a 
result, pralidoxime was rejected by the WHO’s Essential Drugs List (World 
Health Organization, 2009), and an updated Cochrane systematic review 
(http://www.cochrane.org/cochrane-reviews) has reported a lack of evidence 
for effectiveness (Buckley et al., 2011).
Written informed consent was taken from each patient, or their relatives (for 
patients unconscious or under the age of 16), in their own language.
Cohort study.  Patients were identified on admission to 3 Sri Lankan 
hospitals between March 31, 2002, and May 25, 2004, to observe the differ-
ence in clinical features and severity of poisoning for the most common OP 
insecticides (Eddleston et al., 2005). The patients received atropine according 
to a standard protocol (Eddleston et al., 2004) and pralidoxime chloride as a 1-g 
bolus followed by further 1-g bolus doses every 6 h for 1–3 days.
Randomized controlled trial.  The RCT was conducted in Anuradhapura 
and Polonnaruwa district hospitals in Sri Lanka from May 26, 2004, until 
October 18, 2006, to compare the effectiveness of pralidoxime treatment with 
placebo, in addition to standard therapy, in OP insecticide poisoning (Eddleston 
et al., 2009a). Patients were randomized to 2 study arms to receive saline pla-
cebo or pralidoxime chloride. Pralidoxime was given as a 2-g loading dose 
over 20 min, followed by an infusion of 0.5 g/h until a maximum of 7 days, the 
patients no longer required atropine, or death.
For both studies, blood samples were taken from patients before and after 
pralidoxime administration to measure plasma BuChE activity and pralidox-
ime and OP insecticide concentrations. Sampling and assays were carried out 
as described (Eyer, 2003; Worek et al., 1999). The mean control AChE and 
BuChE values in the assay are 586 (SD 5) mU/mmol Hb and 5932 (SD 33) mU/
ml, respectively (Worek et al., 1999). The lower boundary of normal BuChE 
was set at 3000 mU/ml.
Patient eligibility.  For this analysis, we included patients from both stud-
ies who showed biochemical evidence of cholinergic poisoning (BuChE activ-
ity less than 3000 mU/ml) for whom we had proof of the OP ingested and both 
prepralidoxime and postpralidoxime blood sample analyses. Exclusion criteria 
were ingestion of more than 1 OP insecticide, incomplete data files, and a dif-
ferent pralidoxime treatment regimen.
Statistical analysis.  The data analysis was performed in GraphPad Prism 
(version 5). For both cohort and the RCT, cholinergic activities were summa-
rized with counts (percentages) for categorical variables, and the median (inter-
quartile range [IQR]) for continuous variables, as none were expected to be 
normally distributed. BuChE activity at baseline for each agent was compared 
using the Kruskal-Wallis test. BuChE reactivation from baseline to 1 h postpra-
lidoxime was assessed overall and for each agent using a 2-sided paired t test 
and reported as the difference (95% confidence interval [CI] of the difference). 
(Due to the relatively small size of the sample, tests of normality were not per-
formed. Sensitivity analyses using the nonparametric equivalent of the paired t 
test showed no substantial difference.)
RESulTS
Patients were selected from the 2 study databases. Of the 802 
patients in the published cohort study, only 157 had BuChE 
measurements performed (Fig.  1). Ninety-three patients met 
the inclusion criteria (Tables 1 and 2). The RCT randomized 
235 patients, of whom 168 met the inclusion criteria for this 
FIg. 1. Flow diagram of progress through cohort and RCT data. Abbreviations: BuChE, butyrylcholinesterase; RCT, randomized controlled trial.
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study. Ninety-six patients were treated with pralidoxime and 72 
with placebo (Tables 1 and 2).
BuChE Activity on Admission
For patients in both cohort and RCT, there were differences 
in BuChE activity on admission (p < .001). Patients with chlor-
pyrifos poisoning had substantially lower BuChE activity than 
dimethoate-poisoned patients (Table 2) (p < .001). This find-
ing has been previously reported (Eddleston et  al., 2008b). 
Although the number of patients taking fenthion and quinal-
phos was small, both insecticides also inhibited BuChE to a 
significantly greater extent than dimethoate (Table 2; p = .002 
and p < .001, respectively).
Pralidoxime Regimens and AChE Activity
The pralidoxime regimen used in the RCT (2 g loading 
dose over 20 min, followed by a steady infusion of 0.5 g/h) 
produced a measured peak plasma pralidoxime concentration 
of 250 µmol/l at 1 h and a steady state concentration around 
100  µmol/l (Eddleston et  al., 2009a). Plasma concentrations 
were not measured in the cohort study due to the intermittent 
pralidoxime administration. However, the much more rapid 
bolus administration of 1 g in this study (typically over < 1 min) 
would have produced a higher peak pralidoxime concentration, 
than the 2-g loading dose, that would have rapidly decreased 
over time (half-life usually < 1 h).
Both regimens reactivated AChE (Figs. 2A and 3A) as pre-
viously reported (Eddleston et al., 2005, 2009a). Pralidoxime 
1 and 2 g (followed by 0.5 g/h) increased mean AChE activity 
at 1 h by 139 (95% CI 94–184, p < .001) and 170 (95% CI 
134–205, p < .001) mU/µmol Hb, respectively.
Effect of Pralidoxime on BuChE Activity
Assessing the total population of cohort patients, treatment 
with pralidoxime 1 g bolus produced no reactivation of BuChE 
activity at 1 h (Fig. 2B; mean difference 55 mU/ml [95% CI −64 
to 174, p = .36]). Further 6 hourly bolus doses had no apparent 
effect over the first 24 h. Assessing individual OP insecticides, 
BuChE activity nonsignificantly decreased in dimethoate-poi-
soned patients in the first hour (Fig. 2E, mean difference −59 
mU/ml [95% CI −395 to 278, p = .69]). No significant reactiva-
tion occurred in chlorpyrifos (Fig. 2C, mean difference 50 mU/
ml [95% CI −96 to 195, p = .50]), quinalphos (Fig. 2D; mean 
difference 338 mU/ml [95% CI −567 to 1244, p = .36]), or fen-
thion (Fig. 2F; mean difference 5 mU/ml [95% CI −25 to 34, 
p = .66]) poisoned patients.
Assessing the total population of RCT patients receiving pra-
lidoxime of 2 g loading dose over 20 min, followed by 0.5 mg/h, 
BuChE over the first hour was significantly reactivated (Fig. 3B, 
mean difference 416 mU/ml [95% CI 262 to 571, p < .001]). 
The difference was maximal at 1 h and decreased up to 48 h 
as BuChE became re-inhibited. This re-inhibition of BuChE—
despite the steady infusion of pralidoxime—was quite different 
from that seen with AChE, which remained activated after ini-
tial reactivation with this dose of pralidoxime (Fig. 3A).
BuChE reactivation occurred almost entirely in patients poi-
soned with diethyl OP insecticides, because reactivation was 
absent in dimethoate-poisoned (Fig.  3E, mean difference 22 
mU/ml [95% CI −142 to 186, p = .79]) and fenthion-poisoned 
TaBlE 1









insecticide ingested, n (%)
 Chlorpyrifos 71 (76.3) 51 (53.1) 35 (48.6)
 Quinalphos 5 (5.4) 5 (5.2) 5 (6.9)
 Dimethoate 9 (9.7) 23 (23.9) 13 (18.1)
 Fenthion 4 (4.3) 9 (9.4) 10 (13.9)
 Othersa 4 (4.3) 8 (8.3) 9 (12.5)
aOther organophosphoruses insecticides included: phenthoate, diazinon, and 
profenofos.
TaBlE 2
admission Characteristics of Patients Included in the analysis
Cohort RCT Pralidoxime RCT Placebo
Time since ingestion, h; n 3.8 (2.3–5.5); n = 91 4.7 (3.3–8); n = 86 4.2 (3–6.8); n = 71
AChE activity on admission, (mU/µmol Hb); n 107 (32–196); n = 72 34 (11–68); n = 81 33 (7–52); n = 64
BuChE activity on admission, 
(mU/ml); n
All patients 121 (31–343); n = 92 35 (0–36); n = 89 23 (0–166); n = 71
Chlorpyrifos 121 (45–319); n = 70 10 (0–74); n = 45 20 (0–133); n = 34
Quinalphos 11 (6–82); n = 5 10 (0–1149); n = 5 10 (5–350); n = 5
Dimethoate 1245 (501–1754); n = 9 534 (130–1099); n = 23 783 (294–1556); n = 13
Fenthion 10 (4–25); n = 4 10 (3–79); n = 8 1 (0–24); n = 10
Othersa 124 (35–228); n = 4 415 (3–1072); n = 8 35 (5-1344); n = 9
Data are median (interquartile range). Data were collected on admission to hospital; recruitment occurred soon after. Data were not available for all patients.
Abbreviations: AChE, acetylcholinesterase; BuChE, butyrylcholinesterase; n, numbers of cases on which the analysis is based.
aOther organophosphoruses insecticides included: phenthoate, diazinon, and profenofos.
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FIg. 2. AChE and BuChE activity in poisoned patients receiving bolus pralidoxime (1 g bolus every 6 hrs for 24 hrs after admission) (median with inter-
quartile range [IQR]). A, AChE activity for the cohort study patients included in this analysis; B–F: BuChE activities with B, all patients; C, chlorpyrifos; D, 
quinalphos; E, dimethoate; F, fenthion poisoning. Time = 0 is the time of first pralidoxime administration. Abbreviations: AChE, acetylcholinesterase; BuChE, 
butyrylcholinesterase. 
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(Fig. 3F, mean difference 0 mU/ml [95% CI −59 to 58, p = .99]) 
patients. The level of BuChE reactivation was small in chlor-
pyrifos-poisoned patients (to 17% of the lower limit of nor-
mal, Fig. 3C; mean difference 513 mU/ml [95% CI 310 to 716, 
p < .001]), whereas reactivation in quinalphos-poisoned patients 
was nonsignificantly greater (to 36% of the lower limit of nor-
mal, Fig. 3D; mean difference 1076 mU/ml [95% CI −320 to 
2472, p = .10]).
FIg. 3. AChE and BuChE activity in poisoned patients receiving pralidoxime by infusion (2 g loading dose over 20 min followed by 0.5 mg/h; circle) or placebo 
(square) (median with IQR). A, AChE activity for the RCT patients included in this analysis; B–F: BuChE activities with B, all patients; C, chlorpyrifos; D, quinalphos; 
E, dimethoate; F, fenthion poisoning. Time = 0 is time of first pralidoxime administration. Abbreviations: AChE, acetylcholinesterase; BuChE, butyrylcholinesterase.
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FIg. 4. Change in BuChE activity over the first hour from start of pralidoxime treatment in pralidoxime-treated patients in the RCT (2 g loading dose over 
20 min, followed by 0.5 g/h) plotted against time since poisoning. The 2 values from each patient are linked with a line. A, all patients; B, chlorpyrifos; C, qui-
nalphos; D, dimethoate; E, fenthion-poisoned patients. Abbreviations: Pam, patients receiving pralidoxime; Plac, patients receiving placebo; BuChE, butyrylcho-
linesterase; RCT, randomized controlled trial.
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Looking at individual patients, marked variability occurred 
within the general pattern of responsiveness to pralidoxime in 
patients receiving the higher RCT dose (Figs. 4–6). For exam-
ple, some patients poisoned by chlorpyrifos showed increases 
of greater than 2500 mU/ml at 1 h, whereas others showed fur-
ther inhibition (Fig 5A). This variability persisted over several 
days for the 2 most common OP insecticides, chlorpyrifos and 
dimethoate, with and without pralidoxime (Fig. 6).
The relationship between BuChE reactivation in the first 
hour and delay to pralidoxime administration postpoison-
ing or BuChE activity at time of pralidoxime administration 
was assessed for each OP insecticide. With chlorpyrifos, as 
expected, reactivation at 1 h was inversely related to time since 
poisoning (Figs. 4B and 5B). For the other OPs, no such rela-
tion was apparent although there were few patients with quinal-
phos or fenthion poisoning. No relationship between BuChE 
activity at pralidoxime administration and BuChE reactivation 
at 1 h was found (Fig. 5C).
dISCuSSIOn
In this study, we have shown that a bolus of pralidoxime 
chloride 1 g does not reactivate BuChE inhibited by WHO 
class II OPs. In contrast, a 2-g loading dose over 20 min, fol-
lowed by a steady infusion of 0.5 mg/h, reactivated diethyl 
OP-inhibited BuChE although this was not sustained. No reac-
tivation occurred of dimethyl OP-inhibited BuChE. There was 
marked variation between individuals in how they responded to 
pralidoxime. These findings extend the results of these previ-
ously published cohort and RCT.
BuChE reactivation has been used as a marker of pralidox-
ime dosing and therefore efficacy in OP-poisoned patients. 
However, BuChE inhibition is not relevant to the pathophysi-
ology of OP poisoning, and its usefulness would need to be 
linked to either clinical features or an association with AChE 
inhibition (if AChE is a good marker, see below). BuChE activ-
ity is not closely linked to severity in some forms of OP poi-
soning, eg, BuChE can be close to zero in patients with few 
clinical signs following chlorpyrifos poisoning (Eddleston 
et al., 2008b).
This study shows that BuChE activity after pralidoxime 
therapy does not closely correlate with AChE activity. BuChE 
reactivation is much less than AChE reactivation and is not sus-
tained by pralidoxime infusions. AChE activity has been recom-
mended as a useful marker of pralidoxime function (Thiermann 
et al., 2010). However, recently, several findings have produced 
doubts about the usefulness of AChE as a marker for WHO 
class II OP insecticides (Eyer et al., 2010)—a lack of clinical 
benefit despite clear reactivation of AChE in an RCT (Eddleston 
et al., 2009a), a lack of correlation with severity in profenofos 
poisoning (Eddleston et al., 2009b), and a lack of correlation 
with clinical features in a pig model of dimethoate pesticide 
FIg. 5. Change in BuChE activity over the first hour from start of pral-
idoxime treatment in pralidoxime-treated patients in the RCT (2 g loading dose 
over 20 min, followed by 0.5 g/h). A, change in BuChE for each patient, ordered 
by size and OP ingested; B, plot of BuChE activity change versus time since 
ingestion; C, plot of BuChE activity change versus BuChE activity on admis-
sion. Chlorpyrifos (circle), quinalphos (diamond), dimethoate (square), and 
fenthion (triangle). Abbreviations: BuChE, butyrylcholinesterase; OP organo-
phosphorus; RCT, randomized controlled trial.
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poisoning (Eddleston et al., 2012). It is likely to be better to use 
a clinical marker (such as neurophysiological tests of neuro-
muscular junction function) than a biochemical marker to fol-
low pralidoxime (or other forms of oxime) efficacy (Thiermann 
et al., 2010).
We did not measure BuChE aging in these samples. In spite 
of the decrease in reactivation when the time since ingestion 
increased, no correlation was found. In addition, it is unlikely 
that aging was responsible for the very poor reactivation in 
most patients because the in vitro half-life of aging of human 
BuChE for dimethylated and diethylated enzyme, respectively, 
is about 3 and 9 h (Aurbek et al., 2009) and the median time to 
presentation of these patients was 3–5 h. This would suggest 
that a median of 50% of BuChE would be available for reacti-
vation with dimethyl OP-poisoned patients and more than this 
for diethyl OP-poisoned patients.
In vitro studies have been done to measure the reactivation 
of BuChE by pralidoxime for WHO class I and II OP poison-
ings. Jafari and Pourheidari (2006) showed that pralidoxime 
100μM reversed human BuChE inhibition by parathion and by 
paraoxon by about 50%. Rotenberg et al. (1995) showed that 
obidoxime (175 µg/ml) reactivated BuChE inhibited by chlor-
pyrifos by 70% and parathion by 90%. In contrast, other in vitro 
studies have shown that neither pralidoxime nor obidoxime can 
usefully reactivate BuChE inhibited by paraoxon, parathion, or 
methyl parathion (Aurbek et al., 2009; Musilova et al., 2009). 
Due to these findings, Aurbek et  al. (2009) concluded that 
BuChE activity was inappropriate for monitoring the efficacy of 
standard doses of pralidoxime after WHO class I OP poisoning.
BuChE assays can be useful for OP poisoning because they 
may indicate likely exposure and be used to monitor the elimi-
nation of the OP (Eddleston et al., 2008a; Kwong, 2002). The 
liver synthesizes and secretes BuChE continuously; hence, 
an increase in BuChE activity may indicate the absence of an 
inhibiting OP in the circulation and the end of a cholinergic 
crisis (Mason, 2000). This may explain the rise in BuChE 
activity in patients poisoned by dimethoate (an OP that is rap-
idly eliminated) after 48 h. AChE assays would not be a good 
marker of OP elimination because reproduction of AChE will 
occur by erythropoiesis, a slow process with a regeneration of 
less than 1% AChE of normal each day. Cholinesterase status 
after OP poisoning is best established by measuring AChE and 
BuChE activities, re-activatability, and inhibitory activity (a 
marker of active anticholinesterase in the sample; Eyer, 2003; 
Eyer et al., 2003).
In summary, we show that pralidoxime-induced reactivation 
of BuChE is highly variable, according to the dose, OP involved, 
and the individual poisoned. This indicates that BuChE assays 
are not useful for monitoring the effect of pralidoxime treat-
ment in vivo for poisoning with WHO class II OP insecticides.
FIg. 6. Change in BuChE activity for each RCT patient over time, for the two most common OPs. A, chlorpyrifos with pralidoxime; B, chlorpyrifos with 
placebo; C, dimethoate with pralidoxime; and D, dimethoate with placebo. Median and IQR are shown by the thick line. Abbreviations: BuChE, butyrylcholinest-
erase; IQR, interquartile range; RCT, randomized controlled trial.
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